Company · ARTV
Artiva Biotherapeutics, Inc.
Nasdaq's symbol directory lists ARTV on Nasdaq as “Artiva Biotherapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 15 occasions ($10.0M); insiders sold on 16 occasions ($2.3M); 1 planned-sale notice; 4 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- RA CAPITAL MANAGEMENT, L.P. bought $10.0M
- Aslan Fred, Chief Executive Officer sold $1.8M
- Horan Christopher, Chief Tech Operations Officer sold $230K
- Bush Jennifer, COO, CLO, Compliance Officer sold $186K
- Banerjee Subhashis, Chief Medical Officer sold $128K
Every trade (31)
- SELLAslan Fred, Chief Executive Officer sold $260K
- SELLHoran Christopher, Chief Tech Operations Officer sold $44K
- SELLBush Jennifer, COO, CLO, Compliance Officer sold $35K
- SELLBanerjee Subhashis, Chief Medical Officer sold $5K
- SELLAslan Fred, Chief Executive Officer sold $169K
- SELLAslan Fred, Chief Executive Officer sold $422K
- SELLHoran Christopher, Chief Tech Operations Officer sold $71K
- SELLBush Jennifer, COO, CLO, Compliance Officer sold $57K
- SELLBanerjee Subhashis, Chief Medical Officer sold $8K
- SELLAslan Fred, Chief Executive Officer sold $256K
- SELLAslan Fred, Chief Executive Officer sold $690K
- SELLHoran Christopher, Chief Tech Operations Officer sold $116K
- SELLBush Jennifer, COO, CLO, Compliance Officer sold $94K
- SELLBanerjee Subhashis, Chief Medical Officer sold $12K
- SELLBanerjee Subhashis, Chief Medical Officer sold $99K
- SELLBanerjee Subhashis, Chief Medical Officer sold $5K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $248K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $208K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $413K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $596K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $835K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $1.2M
- BUYRA CAPITAL MANAGEMENT, L.P. bought $71K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $1.4M
- BUYRA CAPITAL MANAGEMENT, L.P. bought $58K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $135K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $17K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $275K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $1.1M
- BUYRA CAPITAL MANAGEMENT, L.P. bought $139K
- BUYRA CAPITAL MANAGEMENT, L.P. bought $3.4M
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- FRED ASLAN $246K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Venrock Healthcare Capital Partners III, L.P. 4.2%
- 5AM Ventures VI, L.P. 2.4%
- RA CAPITAL MANAGEMENT, L.P. 37.9%
- RA CAPITAL MANAGEMENT, L.P. 36.6%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition; Costs associated with exit or disposal activities Oct 27, 2026
- Departure or appointment of directors or officers; Submission of matters to a vote of security holders Sep 11, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.